Esperion Therapeutics, Inc. (ESPR), a commercial stage biopharma company, on Monday announced a patent litigation settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Ltd., Hetero Labs Ltd. Unit-V, and Honour Lab Ltd. As per the agreement, Hetero USA has agreed not to market a generic version of Nexletol in the US, prior to April 19, 2040.
Hetero USA had submitted Abbreviated New Drug Application or ANDA seeking approval to market a generic version of Nexletol prior to the expiration of the applicable patents. Nexletol is prescribed to lower cholesterol in blood.
The company said Nexletol patent litigation against the remaining defendants for such as Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Ltd., Dr. Reddys Laboratories Inc., MSN Pharmaceuticals Inc., Renata Ltd; and Sandoz Inc. are ongoing.
Earlier in May, Esperion has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Ltd. to resolve a patent litigation on Nexletol.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.